Pipeline

Our Lead Product

SCV-PHAV: A Therapeutic Vaccine to Treat Peanut Allergy

Safe, short-course treatment, curative results
Preclinical proof-of-concept completed
Simplify vaccine design for clinical development
Initial target market US adults with severe peanut allergy

Compelling Allergy Data

Proof-of-Concept Demonstrated in Preclinical Animal Models using Prototype Vaccines

Demonstrated immune switch in vaccinated mice
Generation of allergen specific “blocking” antibodies
Demonstrated prophylactic potential
Demonstrated therapeutic potential
No vaccination derived adverse or allergic reaction identified in animal models

Other Allergies

Cat Allergy

Seafood Allergy